This report was first published by Endpoints News. To see the original version, click here
The most candid man in pharma strikes again.
When asked on Tuesday’s earnings call whether Pfizer would consider a “transformative M&A” deal in the near or medium term, CEO Albert Bourla said it wouldn’t.
您已阅读15%（293字），剩余85%（1636字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。